Long-term outcomes with tepotinib for clinically relevant subgroups of patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION study: A ≥3-year follow-up

  • Griesinger, F.
  • Ferrara, R.
  • Felip, E.
  • Smit, E. F.
  • Veillon, R.
  • 외 15명
Citations

WEB OF SCIENCE

0
제목
Long-term outcomes with tepotinib for clinically relevant subgroups of patients (pts) with MET exon 14 (METex14) skipping NSCLC in the VISION study: A ≥3-year follow-up
저자
Griesinger, F.Ferrara, R.Felip, E.Smit, E. F.Veillon, R.Le, X.Mazieres, J.Cortot, A. B.Raskin, J.Thomas, M.Reinmuth, N.Yang, J. C-H.Ahn, M-J.Zhao, J.Sakai, H.Viteri, S.Wu, Y-L.Bruns, R.Johne, A.Paik, P. K.
DOI
10.1016/j.annonc.2025.08.2620
발행일
2025-09
유형
Meeting Abstract
저널명
Annals of Oncology
36